NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free KetamineGlobeNewsWire · Oct 19, 2026
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineGlobeNewsWire · Oct 15, 2026
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant DepressionGlobeNewsWire · Sep 30, 2026
Head-To-Head Analysis: BeOne Medicines (NASDAQ:ONC) versus NRx Pharmaceuticals (NASDAQ:NRXP)Defense World · Sep 28, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free KetamineGlobeNewsWire · Sep 15, 2026
NRx Pharmaceuticals: Promising Ketamine Opportunity In PsychiatrySeeking Alpha · Sep 14, 2026NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 17, 2026 | -$0.11 | -$0.44 | Miss |
| May 15, 2026 | -$0.05 | -$0.04 | Beat |
| Mar 23, 2026 | -$0.09 | $0.19 | Beat |
| Nov 17, 2025 | -$0.11 | -$0.27 | Miss |
| Aug 18, 2025 | -$0.15 | -$0.98 | Miss |
| May 15, 2025 | -$0.30 | -$0.34 | Miss |